article thumbnail

Atlas Venture 2023 Year In Review

LifeSciVC

2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. We then shift to the venture ecosystem and the broader capital markets, highlighting the parallels with twenty years ago, post the genomics bubble in 2002-2003.

Science 106
article thumbnail

Biotech Venture Ecosystem: Quick Health Check

LifeSciVC

Indeed, the public equity markets feeling somewhat buoyant for the first time in ages. With a little over 50 new startups raising capital in 4Q24, we’re back to levels not seen for nearly a decade, at the start of the biotech secular bull market in 2013-2014.

Marketing 125
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 2 of 3

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Drugs 69
article thumbnail

How AI and LLMs are transforming drug discovery: part 1

Drug Target Review

For example, in supply chain, when launching a new product to market with limited sales data, domain expertise becomes critical. As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. Raminderpal earned his PhD in semiconductor modelling in 1997.

Drugs 69
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

RNA 52
article thumbnail

How AI and LLMs are transforming drug discovery: part 2

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Science 64
article thumbnail

Zigs & Zags – The Opposite of a Great Idea Can Also be a Great Idea

Perficient: Drug Development

Several books have been written on the concept, and many more refer to it when discussing differentiation and disruption within marketing and product development. It’s common that people view novel and innovative, first-to-market groups as having great ideas. The analogy of the “red ocean” of a saturated market drives home his point.

Marketing 116